OST-122: trials, targets and approvals

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 1/2	NCT04353791 Comparator	Sep 2020 → Dec 2022	ulcerative colitis	Oncostellae S.L	Completed	No outcome recorded

Date	Issuer	Release
2025-02-01	Oncostellae S.L	Oncostellae Receives European Commission Seal of Excellence for OST-122 IBD Project oncostellae.com ↗
2021-09-30	Oncostellae S.L	25-28 Oct 2021 Oncostellae intensifies partnering process at BIO-Europe to outlicense OST-122, a safe and non-systemic JAK3/TYK2/ARK5 inhibitor for IBD oncostellae.com ↗
2020-02-21	Oncostellae S.L	Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis oncostellae.com ↗
2020-02-20	Oncostellae S.L	OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing oncostellae.com ↗
2019-03-24	Oncostellae S.L	23 Jul 2018 Oncostellae initiated clinical development of OST-122 oncostellae.com ↗
2019-03-24	Oncostellae S.L	10 Dec 2018 GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study oncostellae.com ↗

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	OST-122	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04353791 ↗
Action	Inhibit	“Jak3/Tyk2/Ark5 inhibitor” NCT04353791 ↗
Route	Oral	“oral treatment with OST-122” NCT04353791 ↗